46/100
EXT showed high cross-sectional reliability and longitudinal stability. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Research
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
46/100
Four cognitive phenotypes emerged. One phenotype (18% of Aβ+ participants) showed the steepest cognitive decline, highest progression on the CDR, greater baseline medial temporal tau, and fastest neocortical tau accumulation over 4.6 years (hazard ratio [HR] for decline ≈ 2.9). 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our findings suggest that disease progression follows a stage-dependent MVD pattern that can identify at-risk regions. 5 key findings →
Participants: 403 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This paper introduces a novel convolutional neural network model with an attention mechanism to advance Alzheimer disease (AD) classification using Magnetic Resonance Imaging (MRI). 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
46/100
Traditional diagnostic methods for Alzheimer's disease often suffer from low accuracy and lengthy processing times, delaying crucial interventions and patient care. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among 1616 participants (AD = 1498, bvFTD = 118), all algorithms achieved high accuracy (80% to 90%) and discriminatory ability (AUC = 0.89 to 0.95). 5 key findings →
Participants: 1,616 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Significant alterations were observed in 7 lipid classes and 65 specific lipid species in DLB compared to AD. 5 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer’s disease (AD) presents a significant global health challenge, necessitating accurate and early prediction methods for effective intervention and treatment planning. 3 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
BackgroundA novel neuroimaging signature of regional cortical thickness on brain MRI recently showed high potential for Alzheimer's disease and related dementias (ADRD) risk stratification in the community. 1 key finding →
Design: cross-sectional Participants: 3,249 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
After controlling for the level of cognitive impairment, we found a double dissociation between AD clinical phenotype and localization/magnitude of atrophy, characterized by predominant neocortical involvement in EOAD and more focal anterior medial temporal involvement in LOAD. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Differentiation of Alzheimer disease dementia (ADD) and dementia with Lewy bodies (DLB) remains a challenge. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's blood-based biomarker (BBM) tests using single biomarkers or ratios are well characterized, but head-to-head comparisons of multi-analyte algorithmic tests on shared cohorts are lacking. 4 key findings →
Design: cross-sectional Participants: 192 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A valid quantitative imaging method for the measurement of amyloid deposition in humans could improve Alzheimer's disease (AD) diagnosis and antiamyloid therapy assessment.
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Astrocytosis shows a distinct regional pattern in AD brain compared to fibrillar Aβ, suggesting that different types of astrocytes may be associated with the pathophysiological processes in AD. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The logopenic variant of primary progressive aphasia (lvPPA) has been associated with Alzheimer disease, although this relationship is still subject to debate. 4 key findings →
Participants: 16 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Forty-one participants (30 male, 11 female) with a mean (SD) age at death of 75.7 (10.6) years were included. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
White matter structural connectivity was lower in autosomal dominant Alzheimer disease mutation carriers compared with noncarriers and correlated with estimated years to symptom onset. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Clinicians reported high diagnostic confidence in 83% of 18 F-FDG PET compared to 67% for CBF-SPECT (P = 0.001). 2 key findings →
Participants: 126 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Changes in PCC functional connectivity comprised bidirectional alterations in the resting networks in AD-affected brains, and the impaired resting functional connectivity seemed to change with AD progression. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The discordant topography between atrophy and hypometabolism reported in AD is already present at the aMCI stage. 4 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
A 7-min window, corresponding to minutes 1-8 (frames 5-15), produced the highest voxelwise correlation between (18)F-FDG and pPIB (R = 0.78 ± 0.05). 4 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Atrophy of the CC differentiates HE and ID from AD subjects and tracks the cognitive decline of this disease. 4 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Rey's Auditory Verbal Learning Test (RAVLT) is a powerful neuropsychological tool for testing episodic memory, which is widely used for the cognitive assessment in dementia and pre-dementia conditions. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The study of brain networks by resting-state functional magnetic resonance imaging (rs-fMRI) is a promising method for identifying patients with dementia from healthy controls (HC). 2 key findings →
Participants: 89 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
From across this tag
8 of the 838 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 8. The same 8 appear here every time.
- Hierarchical-circular model of biological memory: a multilevel hypothesis for pathogenesis and allostatic integrity in Alzheimer’s disease and related dementias
- Portable, low-field magnetic resonance imaging for evaluation of Alzheimer's disease
- ‘Machine Learning’ multiclassification for stage diagnosis of Alzheimer’s disease utilizing augmented blood gene expression and feature fusion
- MRI-derived brain aging trajectories across the Alzheimer's continuum: links to cognition, pathology and lifestyle risk factors
- Classification of Alzheimer disease, mild cognitive impairment, and normal cognitive status with large-scale network analysis based on resting-state functional MR imaging
- Early and protective microglial activation in Alzheimer's disease: a prospective study using 18F-DPA-714 PET imaging
- The Role of Magnetic Resonance Spectroscopy ( MRS ), Diffusion‐Tensor‐Imaging ( DTI ) and Structural MRI in the Alzheimer's Disease and Mild Cognitive Impairment Diagnosis: A Review
- Positron Emission Tomography Imaging With [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes
Where “Free full text” comes from
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
How the 0–100 score works — and why some entries are capped
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
- Journal tier up to 10 pts
- Journal's citation record up to 4 pts
- Study design up to 12 pts
- Strength of evidence up to 5 pts
- Peer-review validation up to 10 pts
- How recent up to 5 pts
- Sample size up to 4 pts
- Effect reported up to 3 pts
- Studied in people up to 3 pts
- Randomised / blinded up to 2 pts
- Times cited up to 7 pts
- Citations per year up to 5 pts
- Impact for its field and year up to 6 pts
- Cited by studies here up to 6 pts
- Still being cited up to 4 pts
- Senior author's track record up to 4 pts
- Institution's track record up to 3 pts
- Multi-centre collaboration up to 3 pts
- Indexed in PubMed up to 2 pts
- Free to read up to 2 pts
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
What this library is — and isn't
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →